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Background: Disease registries have the invaluable potential to provide an insight into the natural history of the
disease under investigation, to provide useful information (e.g. through health indicators) for planning health care
services and to identify suitable groups of patients for clinical trials enrolment. However, the establishment and
maintenance of disease registries is a burdensome initiative from economical and organisational points of view and
experience sharing on registries management is important to avoid waste of resources. The aim of this paper is to
discuss the problems embedded in the institution and management of an international disease registry to warn
against common mistakes that can derail the best of intentions: we share the experience of the European Cystic
Fibrosis Society Patient Registry, which collects data on almost 30,000 patients from 23 countries.
Methods: We discuss the major problems that researchers often encounter in the creation and management of
disease registries: definition of the aims the registry has to reach, definition of the criteria for patients referral to the
registry, definition of the information to record, set up of a data quality process, handling of missing data,
maintenance of data confidentiality, regulation of data use and dissemination of research results.
Results: We give examples on how many crucial aspects were solved by the European Cystic Fibrosis Society
Patient Registry regarding objectives, inclusion criteria and variables definition, data management, data quality
controls, missing data handling, confidentiality maintenance, data use and results dissemination.
Conclusions: We suggest an extensive literature research and discussions in working groups with different stake
holders, including patient representatives, on the objectives, inclusion criteria and the information to record. We
propose to pilot the recording of few variables and test the applicability of their definition first. The use of a shared
electronic platform for data collection that automatically computes derived variables, and automatically performs
basic data quality controls is a good data management practice, that also helps in reducing missing data. We found
crucial for success the collaboration with existing national and international registries, cystic fibrosis organisations
and patients’ associations.
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A disease registry is a paper list or an electronic database
containing information on the characteristics of a popu-
lation affected by a given disease [1,2]. Disease registries
have become essential for the investigation of chronic
diseases thanks to their potential to epidemiologically
describe the natural history of the disease. They are par-
ticularly useful in rare diseases, such as cystic fibrosis
(CF), where important research questions cannot be an-
swered without large multicentre studies because of the
limited number of patients followed by individual CF
centres.
The importance of disease registries has been ac-
knowledged also by EUCERD [3], an EU Committee of
experts in rare diseases that discusses policies and rec-
ommends activities in collaboration with the EU Com-
mission and Parliament and the Council of Ministers.
Many international projects, such as EPIRARE [4] and
RD-CONNECT [5], promoting international registries
have also been funded by the EU.
The institution and long term management of disease
registries are not trivial challenges, since many key hurdles
need to be overcome. To avoid the garbage in, garbage out
phenomenon, the first step requires the definition of pa-
tients’ inclusion/exclusion criteria: it is vital to determine
whether the registry records only confirmed cases, based
on a set of pre-defined criteria, or whether it is open to all
subjects with a suggestive set of symptoms or signs. The
clinical and epidemiological questions the registry has to
address and the set up of the information system depend
on these criteria. The difficulty in addressing most of
the hurdles is magnified in an international setting,
where agreements on data definition are crucial to ensure
uniformity of data collection across the participating
countries.
Many registries begin on a voluntary and unfunded
basis, being championed by single enthusiasts, but an
effective disease registry requires sustained funding, ad-
equate manpower and an efficient organisational struc-
ture to achieve its main purpose: to describe the clinical
status of patients to foster care improvement [6,7].
The aim of this paper is to discuss the problems em-
bedded in the institution and management of an in-
ternational disease registry, to warn against common
mistakes that can derail the best of intentions. The ex-
perience gained in the establishment and maintenance
of the European Cystic Fibrosis Society Patient Registry
(ECFSPR), that collects data from individual CF centres
and national CF registries from Europe and the neigh-
bouring countries, can be used to show the hidden dan-
gers of disease registries. In this paper we provide
examples on how several crucial aspects were solved by
the ECFSPR in the areas of objectives, inclusion criteria
and variables definition, data management, data qualitycontrols, missing data handling, confidentiality main-
tenance, data use and results dissemination.
Prior to the establishment of the ECFSPR, a pan-
European registry originating from a database set up to
monitor a clinical trial on a respiratory medicine was
used to collect data from approximately 10,000 patients
in 9 countries. This registry was funded by F. Hoffmann-
La Roche Ltd, and was named Epidemiologic Registry of
Cystic Fibrosis [8]. With the termination of funding in
2002, it was decided by CF specialists across Europe,
members of the European CF Society (ECFS), to set up an
independent registry with clear objectives. At that time
several national registries already existed, each built on
separate proprietary platforms, whereas the majority of
European countries did not have a CF registry in place, or
had registries based on one-centre only. In 2003, under
the auspices of ECFS, a working group of representatives
of existing national registries was appointed to set up
this new registry. A pilot study collected data from
seven national registries (Belgium, Denmark, France,
Ireland, Italy, Russia and Sweden), using a simple elec-
tronic spreadsheet. This provided a precious starting
point for data collection, but also showed that different
definitions were separately developed by each national
registry, and even if specifications on data formats and
coding were given, these were not always followed by
data contributors. This aspect, along with the need for
a tool for data entry for countries without a CF registry,
led to the re-evaluation of the data collection system. A
registry steering group was created, in charge of setting
up the structure of the ECFSPR, defining its milestones
and its roadmap.
The first turning point came with the EU funded project
EuroCareCF, that in cooperation with the ECFSPR steer-
ing group set up patient consent forms and collected
demographic data from 35 countries, thereby laying the
foundation for expansion of the ECFSPR outside the exist-
ing national registries [9]. The second and probably most
important turning point came with the support from the
ECFS Board who decided to expand the financial support
allowing appointment of professional staff (coordinator,
helpdesk, statisticians) and lately the development of a
bespoke software building on the experience of previous
data collection and software.Methods
In this section we introduce the major problems that re-
searchers often encounter in the creation and manage-
ment of an international disease registry. Many critical
aspects that we had to face in the activation of this
international registry can be found also in the imple-
mentation of national/local disease registries and they
can be faced in a similar way.
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study
A registry is not an end in itself; it is rather a tool to
reach predetermined objectives, such as enhancement of
knowledge of the epidemiology of the disease under
study, evaluation of different diagnostic and therapeutic
protocols, evaluation and planning of public health re-
sources, creation of health indicators to evaluate the
disease burden and the efficacy of the care [10-12].
The use of registry data is effective and efficient only if
there is a clear definition of the objectives the registry
has to reach and a tracking of the outcomes is carefully
planned. Stepping beyond these agreed objectives could
be problematic especially during the set up phase, because
the community’s expectations might become unachievable
in the time frame of the available funding. In this phase,
estimation of the observation time needed to obtain the
results is a key factor, especially for rare diseases, due to
the risk of having to wait for years before an adequate
number of patients or outcomes are recorded. In a later
phase, when core functions are running smoothly, ob-
jectives can be re-evaluated. Objectives should also be
shareable by the patients whose data are collected in
order to obtain their consent to process their data.
Ideally, a disease registry should only contain data on
patients diagnosed with the disease of interest. This ap-
parently trivial aspect is the core of data collection, be-
cause it determines the uniformity of population under
study and it explicitly defines the data to be recorded.
For this reason, it is crucial to set up an unequivocal
definition of case, which rests upon a general agreement
on the diagnostic criteria [13]. These criteria may be sub-
ject to change over time: often, the change of diagnostic
practices due to advances in knowledge of the disease and
advances in scientific technology change the inclusion cri-
teria to registry referral. The key aspect is to keep an audit
trail of these changes.
Definition of what to measure and how to do it
In the planning of a disease registry, it is necessary to
decide which aspects of the disease are to be recorded
and identify their appropriate indicators. Enthusiasm
often leads to substantial overestimation of the amount
of information necessary to record: it is easy to fall into
the mistake of recording far too much information than
what is actually needed to answer the questions the regis-
try has to address. This is a highly inefficient approach in
terms of time needed to retrieve the data and to register
them into the database, because ultimately the informa-
tion will not be used. The amount of information recorded
is a trade-off between the researchers’ needs and the re-
quirement to keep the registry easy to handle [10]. It is
therefore advisable in the planning phase to clearly define
objectives and to agree on which information has to berecorded. These tasks, if well conducted, make data col-
lection more efficient and avoid frustration in people
who enter the data if the information is not used and
frustration in statisticians who analyse empty databases.
For some rare diseases, the information to be recorded
may be difficult to target because the disease is not yet
fully understood. It is therefore advisable in the plan-
ning phase to select information to be recorded that is
agreed in literature, being aware that new information
could be added in the future.
Definitions for registries have to reflect what is obtain-
able during daily clinical work at various centres, and in
case of international registries, across various countries.
Strict definitions based on well-defined clinical and para-
clinical aspects, as are often implemented in clinical trials,
are often not applicable in the daily clinic, making com-
promises necessary. Unless the data collected are useful to
the clinician or other ways of data collector reward (in-
cluding economic repayment) many registries can fail at
this step.
Data management and data quality controls
To reach its aims, an international patient registry has to
set up an efficient data management system, preferably
automated, that accommodates both national registries’
and individual centres’ needs, coordinating the work of
database managers, statisticians, epidemiologists, and cov-
ering many aspects, such as data collection, data quality
controls, error correction, data analyses and reporting. A
limitation to smooth data streaming for an international
patient registry is that national data registries (or individ-
ual centres) often change their data acquisition systems
and any subsequent data sending to the international
registry requires an agreement between all parties involved
to prevent rupture of the data stream or unwelcome
changes to it.
Data quality control is one of the core data manage-
ment activities of a disease registry and it is probably the
most important aspect because the quality of the data,
together with efficiency of data management, inevitably
affects the quality of research [13]. For this reason, it is
vital for a registry to have accurate data quality controls
and efficient data processing systems in place.
Handling of missing data
Missing data are the bane of researcher’s lives because
they can reduce the precision of the estimates and may
lead to biased results. Missing data are a widespread
problem: in many registries, although there is an ad-
equate completeness level in the demographic data,
there is questionable completeness for clinical follow-up
data [14]. Although there are statistical techniques to
address missing data, it is always preferable to prevent
information loss, therefore it is essential to understand
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much as possible [10,13].Maintaining confidentiality of registry data
The binding element to legally collect data is to obtain
the patient consent to process their data. In order to re-
assure the patients to increase their willingness to give
their consent, it is crucial to ensure that patient’s identi-
fication and data security measures are state-of-the-art,
particularly when dealing with electronic data, that such
measures meet the data protection legislation, and that
they are described and available to the patients. The col-
lection of data into national registries and their potential
export into an international registry must be approved
by the data protection authority in the country of resi-
dence of the patient. An international registry data col-
lection must itself be approved by the data protection
authority of the country of the data controller. The key
aspect is that the data sender must be legally allowed to
send the data and the central registry must be legally
allowed to process the data. The use of data must be de-
scribed in data protection applications and in the patient
consent information sheets; and it is important that the
information given is detailed, but it also has to accommo-
date practical changes during the course of the registry
life: revised applications for the data protection authorities
in case of e.g. a change of data processor can be easily
made, but obtaining the patient consents from all patients
within a short time interval might be impossible. The
registry needs to keep up to date with changing data le-
gislation, nationally and internationally; this is an im-
portant challenge across Europe as new regulations are
about to be enacted [15].Dissemination of the results and use of data
Timely dissemination of results and appropriate use of
data collected are the key elements for achieving the regis-
try primary objectives: enhance knowledge of the disease
under study and promote research. The objectives of a dis-
ease registry also allow use of data for identifying patients
eligible for clinical trials, e.g. patients with a rare genotype.
These patients are of course not to be contacted directly
by the company conducting the trial, but via their care
giver, so anonymity is withheld until the patient consents
to participate in the trial.Results
The results section presents the solutions to the hurdles
described in the methods section, as implemented by the
ECFSPR. The critical aspects and the solutions are sum-
marised in Table 1.Definition of the objectives and of the population under
study
Definition of the objectives
During the set up meetings of the first working group of
the ECFSPR, the objectives of the registry were thor-
oughly discussed and agreed, as stated in the ECFSPR
website and in patient consent [16]: “The purpose of the
ECFS Patient Registry is to measure, survey and com-
pare aspects of cystic fibrosis and its treatment in the
participating countries, thereby encouraging new stan-
dards of dealing with the disease, to provide data for epi-
demiological research and to identify special patient
groups suitable for multi-centre trials. The information
will facilitate long-term planning of health expenditure
allocations and developing pan European support sys-
tems”. When defining the objectives it is important to
include all stake-holders in the process. For a patient
registry relying on the patients acceptance of their data
being collected, we found it crucial to involve patient
representatives very early in the project; for this reason
we cooperated closely with CF Europe, the European CF
patients’ organisation, who appointed two of their asso-
ciates as members of the steering group, one of whom is
also member of the executive committee.
Definition of the population under study
Due to the international nature of the ECFSPR, the first
concern was to ensure that the registry collected data
from patients meeting uniform inclusion criteria across
countries. A working group was set up with the aim of
defining the inclusion and exclusion criteria for CF pa-
tient referral to the ECFSPR. This was a small group,
whose tasks included extensive literature research, re-
trieval of necessary information from CF registries repre-
sentatives and database managers, and harmonisation of
criteria.
The diagnostic criteria for CF are not internationally
agreed and, often, their verification is not strictly per-
formed in clinical practice, mainly due to costs. For ex-
ample, sodium and chloride concentrations in an agreed
sweat test protocol are considered gold standards for the
diagnosis of CF [17], but a quicker method of estimating
sweat chloride (conductance) was introduced, even if
it has never been recognized as equivalent to the con-
centration measurements [18]. However, this method
is widely used as a screening tool and may be the only
sweat test performed on a patient. Moreover, improve-
ments in DNA analysis resulted in the diagnosis of both
patients on whom sweat test was never performed (e.g. be-
cause two known disease causing mutations were found
by DNA analysis) and patients with clinically milder forms
of CF or CF-like syndromes, opening the debate in the
international scientific community about the definition
of CF [19].
Table 1 Overview of critical aspects when setting up a registry and the solutions implemented by European Cystic
Fibrosis Society Patient Registry
Critical aspects Solution
Definition of the objectives of the registry Discussion on the objectives in a working group involving different stakeholders, including patient
representatives
Definition of the population under study
Definition of inclusion criteria Extensive literature research, retrieval of necessary information from existing registries,
harmonisation of criteria made by a working group, adoption of an operational definition that
could be used as inclusion criteria for the registry purposes
Assessment of whether patients registered
meet the inclusion criteria
Ideally, recording of all the information necessary to check diagnosis, but, operatively, assessment
delegated to the data contributors who have to confirm that the inclusion criteria are met
Definition of what to measure and how to
do it
What to measure Review of literature and discussion on variables definitions in a small working group of experts
How to measure Start data collection of few variables and test with a pilot study the applicability of their definition
If the definition used is not the same across countries:
• try harmonisation by making the definition more generic
• involve stakeholders to discuss change of definitions and agree on a shared definition
• if definitions can be assimilated, report differences of definitions in the publications as caveats
Data management and data quality controls
Data management Shared electronic platform for data collection with automatic computation of derived variables,
allowing both direct data entry and remote data upload.
Use of technology (such as XML) that ensures that required data format and coding is used.
Data quality controls Automatic and immediate data quality controls on entering (plausible ranges, intra-record data co-
herence, and consistent information across years.)
Use of drop-down menus with fixed input possibilities (e.g. yes/no/unknown)
Agreed controls with national registries in order to avoid duplication of identical data quality
control processes.
Use of refined data controls based on age-and-sex-specific reference values
Set up of a data error procedure that uses a software that automatically warns and points the user
to the data to correct
Handling of missing data User-friendly software and useful feedback to contributors to encourage data entry
Clear definitions, but attainable in daily clinical practice
Unequivocal exhaustive variable coding with no pre-set values
Avoid the use of tick boxes that code missing answers and negative answers the same way
Working with existing registries to accommodate definitions
Maintaining patient confidentiality Separate storage of encrypted personal data and anonymous centre numbers
Pseudo-anonymisation to allow contact with centre for error correction
Dissemination of data Code of conduct document concerning publication rights, authorship and data access – preferably
set up very early in the process
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ition that could be used as inclusion criteria for the
registry purposes. The fundamental aspect in fact is that
the population under study is uniform in terms of inclu-
sion criteria, even if the official clinical definition might
not be met, because this does not have an impact on
research and appropriate subgroups can be selected for
further study.
Ideally, the ECFSPR should record all the information
necessary to assess whether the patients registered meet
the inclusion criteria or not. However, the level of detailof information needed resulted in a lot of missing data
from the pilot data collection, especially from the na-
tional registries, that often did not record such detailed
information. The verification of the inclusion criteria
was therefore delegated to the data contributors, who
had the opportunity to check the clinical notes in a
more efficient and timely way, and the ECFSPR data col-
lection requires each participating country/centre to
confirm, for each patient referred to the ECFSPR, that
the inclusion criteria are met. The data senders therefore
take responsibility on the appropriateness of referral,
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ECFSPR.
Definition of what to measure and how to do it
Definition of what to measure
In the ECFSPR experience, the task of defining variables
was particularly complex and time-consuming, due to
the international nature of the registry and the fact that
many countries had already established national regis-
tries using internally-chosen definitions. A small group
of people was put in charge of revising the literature
about the definition of critical variables and discussing
the implementation and the adaptation of clinical defini-
tions. The intention of this working group was to collect
a limited set of key variables that would make it possible
to achieve the ECFSPR objectives.
We first undertook the pilot data collection from the
existing national registries to estimate the feasibility of
collection of such variables. The participants were asked
to send information for 49 variables. The proportion of
missing data varied according to the type of information
requested: basic demographic data such as gender, year
and month of birth were reported on all patients,
whereas more detailed social and clinical information
such as marital status or use of continuous inhaled anti-
biotics was missing for almost all patients. This pattern
was mostly due to some national registries not recording
information on the variables required by the ECFSPR.
Based on this collection, the definitions group put for-
ward a revised set of variables for the collection of data
for years 2004/2005.
Definition on how to measure
The ECFSPR could not always follow the golden rule
according to which the choice of indicators should fall
on those easy to observe and with unanimous definition.
Often the best indicator was not the easiest one to ob-
serve: in this case, it was not included in the registry,
due to the high risk of having a lot of missing data,
obtunding the efforts of data collection. Particularly useful
was the approach to have in the database few variables
and test with a pilot data collection the applicability of
their definition. Also, if the best indicator has different
interpretations in the scientific community, there is the
risk of putting under the same roof different quantities,
making interpretation of results impossible. Some case
examples are:
 Medication: asking quantitative information on the
dose of pancreatic enzymes taken by CF patients is
clinically useful and it would be highly informative,
but the intake of this medication is often variable on
a meal to meal basis and estimating a “daily intake
value” (or a “yearly intake value”) would beextremely difficult. The definitions working group
felt it was appropriate to replace this information
with a more generic “use of pancreatic enzyme ever
in the follow-up year”;
 Complications: an important prognostic factor in CF
is chronic infection with Pseudomonas aeruginosa.
Several definitions of chronic infection have been
used in daily clinical care as well as in publications.
The most commonly used is the Leeds definition
[20] or a modification of this. However, this
definition requires several sputum cultures per year,
and patients who were diagnosed with chronic
infections for a long time and on continuous
inhalation therapy may not fulfil the strict criteria,
although they would still be classified as chronically
infected by their care givers. Therefore, the
definition on diagnosis of chronic infections for the
ECFSPR purposes had to be an operational
definition [21] that allowed discrimination only
between patients with chronic infection from those
patients without infection and/or with intermittent
infection.
Collecting about 85% of its data through national
registries, which have already collected data from the
CF centres following the national registry definitions,
not necessarily the same as those of the ECFSPR, is an-
other challenge. Whenever possible, we used a defin-
ition that would comply with most national registries.
However, some of them could not be harmonised and
for those the national registries have chosen either to
report this variable as missing (e.g. one registry records
only “Pseudomonas aeruginosa cultured this year” with
no chronicity defined), or to change their definition to
comply with the ECFSPR one. For example, several coun-
tries are now collecting the best value of FEV1 of the year,
as required by the ECFSPR, instead of last of the year or
the value registered at the annual assessment. If definitions
are not the same across countries, but can be assimilated,
this is reported in methods sections of manuscripts and
written in notes appended to tables and graphs.
Data management and data quality controls
Data management
Figure 1 schematically shows how the ECFSPR data collec-
tion is organised. In order to provide a common platform
for data collection, bespoke software was developed. It is
composed of two tools: one for data upload from national
registries and one for manual data-entry for countries that
do not have a national database. In both cases, the data
are stored on a central server, located in secure premises.
The current data-entry software, which has been used for
3 years of data collection, has some limitations and new
software is currently being rolled out across Europe,
Draft
database
National
CF registry
Automatic
database upload
errors?
Individual
CF centre
Manual
data entry
errors?
yes yes
no no
yes yes
Controls 
performed by 
the software
Controls 
performed by 
the Data 
Management 
UnitFinal
database
errors
no
?
Figure 1 Flow-chart of data collection and data quality controls of European Cystic Fibrosis Society Patient Registry.
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tioning has not changed.
Acquisition of data The data upload from national
registries is performed through the Extensible Mark-up
Language (XML), a strategy adopted by the ECFSPR in
2010 to overcome the inefficiency in the coding of data
from national registries. In fact, this choice of language
forces the variables formats and specifications to be met,
saving a lot of data management time to the ECFSPR Data
Management Unit (DMU). Once the national registries
have prepared the data extract from their database accord-
ing to the agreed definitions and coding, they upload the
XML file they created, and a two-step system validates
the file according to a procedure described in the next
section. The use of the XML procedure has as big limi-
tation the need of an IT-specialist to create the XML file
from the data extract made by the national registry data
manager. In the ECFSPR experience, this aspect was a
bigger obstacle than anticipated, both practically and
psychologically. This made us rethink the upload
process in the development of the new data-entry soft-
ware, focusing on user-friendliness and ease of use with-
out compromising on coding requirements. The new
data-entry software allows uploading data files in differ-
ent formats in addition to XML (such as comma-
separated values, and common formats that are easily
originated from the national databases) and controls on
data coding and value ranges are performed on these
files.
The manual data-entry is performed as follows: the
software sends the patients’ data, except the identifiers,to a web server. The data are anonymised through the
creation of a randomly-generated code. The identifiers,
like name and full date of birth, are stored in an encrypted
form on a server, but only the centre holds the key to de-
crypt the data. The rest of the database is also stored in
an encrypted format and it is password-protected. Some
data-quality controls are automatically performed by
the software, which warns the user by means of flagged
fields whenever discrepancies are found and when items
are left blank. Further details on automatic data quality
controls are described in the next section. One limita-
tion of the current software is that the non-anonymous
data are stored at the local hospital computer. This
caused significant problems with installation and up-
grading working with doctors and IT-technicians from
many centres in many countries. In the new software,
the identifying data are stored encrypted on the central
server or on a national server, but only the centre holds
the de-cryption key to view the data, and they are not
accessible in any way by the ECFSPR. In case the user
loses the identifying data, they will have to re-enter
them whereas the rest of the data will always be
accessible.
Raw data and derived variables Good data manage-
ment practices impose that derived variables, such as
BMI, are centrally computed by the DMU. The main
reason for this is that, should an error in the computa-
tion occur, it would be easily traceable and recoverable.
In order to minimise data-entry errors, it was decided to
collect raw data (to which automatic plausibility checks
are carried out) and delegate the computation task to
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the further advantage that the raw data can be trans-
formed into standardised values (such as FEV1% of
predicted, or height/weight standard deviation scores)
according to different reference equations, as needed.
Data quality controls
Basic data quality controls should initially check that
entered values lie within plausible ranges. Intra-record
data coherence must be checked, such as chronological
sequence of dates (e.g. the date of diagnosis has to fol-
low the date of birth unless pre-natal diagnosis was
performed) and consistent information (e.g. if values
for a test are present, then the test must be recorded as
“performed”) also across years (e.g. patients reported
as liver transplanted one year should still be reported
as transplanted throughout all subsequent years).
The ECFSPR has implemented a data quality control
procedure composed of two levels: one carried out by
the software for data entry and another carried out by
the DMU.
First level of data quality controls (performed by the
software) For the manual data entry, correct coding is
obtained by dropdown menus with fixed input possibil-
ities (e.g. yes/no/unknown). The only field allowing free
text is the mutation field: with more than 1900 known
CF mutations, only the most frequent ones are included
in a drop-down menu, with the possibility to manually
enter new ones as free text. For numeric values, the for-
mat must be correct (e.g. integer, decimal, date), and
the value should be within a pre-set range or it will not
be accepted. Furthermore, values outside certain age-
specific ranges will be flagged as possible errors, but
will be accepted. For example, any value of height
within the range 35–250 cm is accepted by the software,
but a one-year old boy recorded as 100 cm high would
be outside the age-specific range of 67–79 cm. His
height value would therefore be accepted by the soft-
ware but it will be flagged as a probable error to the
user.
For the users who send the data through file upload
we originally implemented the same controls, with upload
denied for patients with unacceptable values and an error
report of the problems. This could result in national
registries not being able to finish uploading the full data
set until errors had been corrected and re-uploaded. For
this reason, we subsequently adopted another approach,
described in the next section.
Second level of data quality controls (DMU) The sec-
ond step of data quality control procedure is identical
for the two means of data sending and it is carried out
after the annual data collection is closed. The DMUcarries out more refined data plausibility and data coher-
ence controls, for example, by using reference values for
height and weight to detect potential errors by means of
standard deviation scores, or by comparing values across
years (e.g. decreasing values for height). The errors
found are then uploaded onto the ECFSPR server as a
file that points directly to the patient and the erroneous
values with a short explanatory text. When opening the
software, the users are led straight to the error and can
either correct the value or confirm it; with a free text
field available to send messages of explanation to the
DMU.
When inconsistent data are found, data contributors
should receive notification to revise data and send cor-
rections within a pre-agreed short time frame. It is im-
portant that such notification is performed as quickly as
possible. Mehta [14] reports that two weeks is a practical
time limit by which centres should receive notification,
because within this time people in charge of data-entry
effectively remember the clinical notes and are able to
retrieve the necessary information to correct the data.
After this time, correcting the errors becomes less timely
and efficient. This process becomes even more burden-
some when requests of clarifications do not go directly
to the centres that entered the data, but to intermediate
data-management units (such as national registries).
For the centres manually entering the data, automatic
data checks help avoid entry of wrong data, and since
the patient’s file is usually available during data entry,
the user can quickly find the correct value. In the new
software we have added even further automated con-
trols, diminishing the need for further corrections by the
DMU.
For the national registries, however, the two-level data
control turned out to be very inefficient. For a lot of the
corrections requested, they need to contact the individ-
ual centres in their country – maybe even twice if errors
were found in both levels of data control. This process
could be very long and inefficient particularly if the na-
tional registries have already performed their own data
quality controls and frozen the database for the analysis
when the ECFSPR data collection starts. This is a spe-
cific issue for the ECFSPR, since we collect data with a
delay of three years at the moment. The delay is primar-
ily to allow the national registries to perform their data
cleaning process and produce their own report before
sending data to the ECFSPR. We aim to minimize the
delay to one year. In order to optimize the error correc-
tion process a data quality control group, composed of
national registry data managers and the ECFSPR team,
has agreed on a common and exhaustive list of internal
data checks to be carried out on the national databases
by the national registries during their internal data
cleaning process before data upload to the ECFSPR [22].
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data set without interruption and will just receive a list
of any remaining questionable values.
After all the errors have been corrected by the data
contributors, the data are frozen for analyses. Potential
errors found by ECFSPR but not confirmed/corrected by
the user, for the purposes of the annual data report, are
deemed as erroneous and are set to missing.
Handling of missing data
The amount of missing values has an important role on
the interpretation of the results: if the data are missing
for a non negligible portion of the database, then the es-
timates can be very imprecise or even biased if the
underlying missing data mechanism is related to some
specific values. For example, if 10% of the patients are
reported to use insulin, but 20% of patients have un-
known/missing information on use of insulin, the true
percentage of use of insulin can be anything between 10
and 30%. For the annual ECFSPR data report we always
report the number of missing data to illustrate the prob-
lem. The long experience of the ECFSPR team reveals
that there are several reasons why missing data occur:
1. The lack of protected time, motivation and funding
by a dedicated trained person in charge of data
retrieval and data-entry is the biggest reason for the
occurrence of missing data. Information not recorded
at recruitment is rarely retrieved afterwards: data
already entered are only occasionally revised by the
CF centres, and their modification is performed only
upon explicit request from the ECFSPR DMU. For
example, some CF centres that send the data to the
ECFSPR did not enter the information on the vital
status of the patient (deceased/alive); when the
ECFSPR DMU asked the centres if really the vital
status of their patients was unknown, the centres
answered that they did not have the time to enter
this information, but that all the patients they
reported were alive. The type of information
requested and the time when the revision is
requested are two critical points in the data
correction process. There might be the need to
consult the original clinical records and, sometimes,
this can be problematic, especially if the time lapse
is long. One way to reduce the workload for data
entry is to automatically extract the information
necessary for the registry from the computerised
case report system that is used by a the CF centre.
This has the advantage that if the data entered are
used for clinical purposes, the centre operators are
motivated to enter good-quality data for their own
use. This solution was not applicable to the
ECFSPR, due to the big heterogeneity of CF centres’IT systems. With the implementation of the new
data-entry software, though, we paid attention to
create a user-friendly tool that could be used in
clinical practice. Although it may not replace the
software for patients management within the CF
centres, the availability of a tool that allows users to
see graphs of patient’s outcomes over time, centre
data reports, and to download their centre’s data,
hopefully will boost the motivation to actively
participate to the ECFSPR by entering good quality
data as well as reducing the amount of missing data;
2. The second reason for missing data is poor variables
definition or misunderstandings in their coding. For
example, the reason for some missing data on
chronic infections in the last ECFSPR data
collections was due to the fact that definition stated
that culture was on sputum samples, and some
centres interpreted this as only sputum and not
cough swaps or other means of sampling, and hence
left the variable as unknown if cultures were
obtained by these other methods. The coding of
liver disease also created missing values problems:
the ECFSPR codes liver disease as (a) absence of
liver disease, (b) presence of cirrhosis with
hypertension, (c) presence of cirrhosis without
hypertension, (d) presence of cirrhosis without
specification of hypertension and (e) liver disease
without cirrhosis. In the 2008–2009 data collection,
one national registry collected and coded liver
disease only as either presence or absence of
cirrhosis with hypertension. This led to an
incomplete classification of patients according to the
ECFSPR criteria, because it was not possible to
establish whether patients who did not have
cirrhosis with hypertension were classifiable as code
a, c, d or e;
3. The third reason for missing data is the poor
specification of data fields: if a multiple-choice
questionnaire does not provide the full range of
possible answers, the operator that fills in the form
can find it difficult to answer a question. A good
way of avoiding this problem is to pilot the survey:
sometimes the range of possible answers becomes
clear only after answering the question in real settings.
During such a pilot, we realised that recording
information on neonatal screening test as positive
or negative only was not exhaustive, because the
test can have been performed and the result be
positive, it can have been performed and the result
be negative, it can have been performed and the
result be unknown, it can have not been performed
and it can be unknown whether the test has been
performed or not. Thus we expanded the two
original possibilities to five;
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yes-no question only when there is an affirmative
reply (sometimes aggravated by the software with
only one tick box implying that an un-ticked box
means no). This makes it hard to distinguish
between true negatives (no), true unknowns (the
user doesn’t know the information, so they
deliberately leave the field untouched) and the
omissions (the user forgot to answer the question:
the answer could be either yes or no), as described
by the insulin example above. From the beginning,
the ECFSPR data collection form has required an
active answer to all questions, without any pre-set
values;
5. The fifth reason of the occurrence of missing data is
the fact that not all the national registries collect the
same variables, therefore some information is
missing for some countries. For example, in the
2008–2009 data collection, for five countries the
information on the use of inhaled hypertonic saline
is missing because such information is not collected
in a systematic way. In other cases the national
registry definition is so different from the ECFSPR
definition that the country chose to set the whole
variable to missing, such as happened for one
country with the information on chronic infection
by Pseudomonas aeruginosa;
6. A final reason is the lack of information for
particular sub-groups of patients due to specific
patients’ characteristics. These are, for example,
adults that do not have access to an adult CF centre
and are lost to follow-up after leaving a children’s
clinic, or transplanted patients who move from a CF
centre to a transplant centre that does not
participate to the registry. In the ECFSPR
experience, there have been anecdotal reporting of
the last group of patients from one national registry,
but a thorough investigation of the problem has still
to be carried out.Maintaining confidentiality of registry data
Anonymity of the individual patient is fundamental both
in the patient’s decision to consent to their data use, and
in the management of the data. This is particularly im-
portant in a rare disease where the number of patients is
limited. Patient identifiers such as name, address and full
date of birth are very rarely needed for the aims of any
disease registry, as long as the patient can be identified
for error correction by the patient’s care giver, who is
privy to this information. Therefore, partial anonymisa-
tion (often called pseudo-anonymisation) can be used,
whereby a patient ID can be linked to the full patient
data only at the hospital site.This poses other problems that need to be overcome:
local handling of consents (because the signature on the
consent form would disclose the patient’s name) and
tailored software solutions (the local care giver must see
the name of the patient while entering data to avoid
confused identities, but the name cannot be sent to the
central database).
The anonymity of data stored in the ECFSPR data-
base was guaranteed by two means: access to person-
identifiable data is granted only locally (CF centre or
national registry) and creation of a random EU centre/
country number so that the centre is not identifiable in
the database. For national registries, no person identifiable
data are transferred, but for the individual centres, who
needed to see the patient name in order to enter the data
correctly, these data are stored separately and encrypted
without means of access from the ECFSPR team. The cen-
tres or national registries have all been issued a random
centre. The link between the centre number and the
centre name is held by the helpdesk personnel and the
centre names do not appear in the registry database,
thus enhancing anonymity also for patients attending
very small centres.
Dissemination of results and use of data
Timely dissemination of results and appropriate use of
data collected are the key elements for achieving the
registry gold objectives: enhance knowledge of the disease
under study and promote research. There are several ways
through which results can be disseminated: publication of
technical reports, communication at conferences and pub-
lication in peer-reviewed journals. The use of data should
be governed to avoid misuse of data. For this purpose the
ECFSPR developed an initial set of guidelines, a code of
conduct and terms of reference documents endorsed by
the participating countries [23-25].
Annual reports
The ECFSPR annually publishes epidemiological descrip-
tions of the data in a technical report, usually presented
during the annual European Cystic Fibrosis Society Con-
ference and subsequently available from the ECFSPR
web site [26]. Frequency tables, descriptive statistics and
graphs give updates on main aspects of CF epidemiology
such as demographics, diagnosis, genetics, lung function,
nutrition, microbiology, complications and mortality.
Results are presented at European level and separately
by country, to allow comparisons.
In the latest issue of the annual data report, a special
effort was made to make the report contents more
patient-friendly than in the previous issues: we used tech-
nical jargon only when necessary, we commented tables
and graphs, we provided instructions on how to read more
complex graphs (such as box-plots), and we added a
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features a section dedicated to patients, containing a mes-
sage from the ECFSPR team and an invitation to send
comments.
Another reporting activity, fundamental in a disease
registry activity, is the feedback on the data given to the
data contributors. This has the double advantage of im-
proving data collection and empowering data contribu-
tors. The ECFSPR sends to the participating CF centres
a customised report summarising the centre’s data and
comparing them with data from other centres in the
same country and with data from other countries. This
gives the data contributor a report of the quality of the
centre’s data and, most importantly, the status of their
patients compared with other centres. Data comparisons
are performed in an anonymous way: the centre names
are not disclosed, safeguarding confidentiality of each
centre’s aggregated data.
Peer-reviewed publications
Publication in peer-reviewed journals is probably the
most efficient and effective way to share with the scien-
tific community the findings of research and submit it to
its scrutiny.
The scientific activity of the ECFSPR allowed, for ex-
ample, enhancing knowledge on potential risk factors
of pulmonary disease in CF patients, highlighting the
importance of their early identification and timely
intervention [27].
The availability of a large database, such as the ECFSPR,
offers a unique opportunity to analyse data from different
populations. This opportunity was fully exploited to
provide the CF specialists with a useful additional tool
for patients care: Boëlle et al. [28] published reference
percentiles for FEV1 and BMI derived from a CF popu-
lation. This allows CF specialist to have additional infor-
mation on the patients they care for by comparing their
lung function and BMI with their CF peers instead of
against a healthy population alone.
Another important area of research activity is providing
information for therapy development. This fundamental
contribution was achieved in another publication [29],
where the authors describe the CFTR mutation class
spectrum across Europe, highlighting which are the muta-
tion classes to target for drug development in order to
maximise the number of patients that will benefit from it
and pointing out in which countries clinical trials could be
performed thanks to the availability of patients carrying
specific mutations.
Finally, research outcomes have the potential to urge
for political decisions that have an impact on CF patients’
life. The paper by McCormick et al. [9] is an example of
how comparison of simple demographic indicators high-
lights health care inequalities: the authors in fact showedthat very different age structures of CF patients were ob-
served between countries, despite a common genotype,
according to their longevity of European Union member-
ship, suggesting that health-care spending in new EU en-
trant countries would correspond to improved survival of
patients.
Access to data
Making the data available to the scientific community
for research purposes is a noble and a burdensome re-
sponsibility. Granting access entails the responsibility to
provide high quality data and ensuring legal and ethical
use of the data by third parties.
The ECFSPR decided to grant access of the data only
after some years of its activity, when crucial issues on
uniformity of definitions and data completeness had
been resolved. Access is strictly regulated by a Standard
Operating Procedure, according to which requests on
the use of data are reviewed by a scientific committee
that formulates a recommendation for its approval and
the request is forwarded to all the data contributors that
ultimately give permission to use their data. A clear
authorship, acknowledgement and publication policy has
been set up, to ensure fair recognition of people’s work
and contribution [24]. The data collected by the ECFSPR
are at the moment being analysed in order to estimate
the need for and plan the care of adult CF patients in
the future (ERS/ECFS Task Force on Adult Care in
Cystic Fibrosis).
Discussion
There are some critical points in a disease registry devel-
opment that are independent of resource allocation and
that should be carefully considered in the planning
phases of a disease registry.
The first important point is the definition of the infor-
mation to record. The experience gained by the ECFSPR
definitions working group proved that the most cost-
effective approach is to first work on the definition of a
few variables, then pilot the definition for data collection
on a restricted group of data contributors or for one
data collection point, make the necessary amendments
and then move on with the definition of other variables.
This sequential approach, as opposed to the one of com-
pleting the full set of definitions in one go, has the ad-
vantages of not delaying the data collection for too long:
if definitions are agreed on a core set of variables of high
research interest first, data collection can start straight
away, instead of being postponed by the time needed to
define other, less important variables. The initial ECFSPR
pilot study highlighted the importance of having common
definitions for the variables to collect. If we had started
data collection before already established databases from
national CF registries, fewer compromises would have
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information collected, but such an opportunity is probably
not available for most rare diseases. In order to set up defi-
nitions that would make data analyses results useful and
at the same time data retrieval from clinical files feasible,
we had to sacrifice some of the internationally acknowl-
edged definitions; in some cases, to avoid large amount of
missing data, we had to use proxy variables, such as use of
pancreatic enzymes as a proxy for pancreatic insufficiency
in order to guarantee fair comparisons across countries. In
the most critical cases, national registries recorded infor-
mation according to internally-agreed definitions, and
where compromise was not feasible we had to content
ourselves with missing data from those countries where
their definitions were too far from what we intended.
Fortunately, the national registries have been very col-
laborative, sometimes even changing their definitions to
accommodate the ECFSPR ones in order to reduce the
amount of missing data. Involving the national registry
representatives in the definitions workgroup has been
crucial for this understanding. For this reason we en-
courage researchers willing to set up disease registries
to have early meeting with all potential data contribu-
tors, and to start a collaborative relationship. Finally,
the ECFSPR definitions group advised a periodic revision
of the information registered. This task is considered fun-
damental for an efficient perspective data collection, for
three reasons: (1) definitions need often to be validated in
real settings, and in some cases clarifications are necessary
to people in charge of data retrieval and data recording;
(2) variables might prove to be of limited utility for re-
search due to the way they have been defined or coded;
(3) improvements in knowledge of the disease and ad-
vances in scientific/technological discoveries make the
collection of new information necessary: the registry
needs to be constantly in tune with changes, to avoid
that the information collected is no longer useful to re-
searchers and clinicians. The ECFSPR is starting the
second revision of its data collection form, reviewing
the definition of some variables (such as diabetes) and
evaluating the inclusion of new ones (e.g. computerised
tomography imaging and lung clearance index). It is im-
portant to remember that such revision and the choice
to modify the information collected has an impact on the
data already collected: careful examination of whether
there will be limitations in linking the data across the years
should be performed. Similarly, when choosing to add new
information to data collection, the effort needed to retrieve
such information for the patients already included in the
registry has to be carefully evaluated. For these reasons,
the ECFSPR will have to carefully balance the advantages
and disadvantages of modifying the data-entry forms.
Although adoption of common definitions, together
with the use of a common data collection platform,should guarantee comparable data across countries, dif-
ferences in outcomes between countries can still be ob-
served, and there is a risk of over- or mis-interpreting
these. They can be due to many factors, like different
population demographics, health care systems, standards
of care and national economics. These are the true dif-
ferences that should be discussed and used for improve-
ment of CF outcomes. However, differences may also be
due to measurement methods and different translation
of clinical findings: observational studies (such as patient
registries) are more prone than other study designs
(such as clinical trials) to the risk of artificial differences
due to e.g. different measurement instruments or meas-
urement practices. When such heterogeneity is observed,
it is advisable that the registry validates the data to en-
sure that the differences seen are real. For example, in
the ECFSPR 2008–2009 data collection, we found bigger
differences in liver disease severity than expected from
the natural history of this complication. For this reason
the ECFSPR recently started a project on liver disease
investigating the diagnostic work-up performed on ran-
domly chosen patients and centres participating to the
ECFSPR. Also, the ECFSPR decided to use internation-
ally agreed reference values for pulmonary function and
anthropometric measurements, but there is the aware-
ness that such choice is not appropriate for all the CF
populations registered in the ECFSPR, therefore standar-
dised values are used only when comparison between
countries are carried out, and careful comments always
accompany the outcomes of such comparisons.
Another crucial aspect in a disease registry develop-
ment is the careful consideration of the growing registry
needs. With 23 countries, almost as many languages and
the reality of working with both national registries with
more than 5,000 patients and small centres with less than
50 patients, the ECFSPR had to face many challenges. The
choice of an electronic data collection system eased the
data-recording process, but it triggered the recruitment
of additional workforce (IT experts, helpdesk staff for
technical assistance) and the need of technical devices
(e.g. server) that need maintenance. The software for
data-entry must fulfil standards of quality and security,
it should be tailored to the needs of the registry, and it
should be user-friendly. Ideally, the physicians should
use the data collected through the software in the daily
patient management, thus rewarding them directly for
the data retrieval and data-entry effort. The patients
that consented to have their data collected should be
given graphical feedback through the software, to see
the benefits of participation to the registry. The first
software adopted by the ECFSPR was quite demanding
in terms of on-site installation and maintenance, and
the burden on the centres as well as the technical help-
desk was considerable. This was an important lesson
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multilingual helpdesk approach has been necessary even
if the official language of the registry is English. The devel-
opment of standard operating procedures, the drafting of
technical documentation, and the use of document-sharing
technologies and web teleconferencing have proven very
effective in the daily management of the operational ac-
tivities of the ECFSPR. This increased complexity in the
registry structure has to be carefully considered by re-
searchers, and an accurate cost-benefit analysis should
be performed, especially when the funding opportunities
are not secured. At the moment, the ECFSPR employs
one full time coordinator, one full time statistician and
two part-time help-desk personnel. Additional cost of soft-
ware development will vary depending on the need. Fur-
ther to this, the cost of running the national registries may
be even higher in the larger countries, whereas some
smaller countries rely almost entirely on volunteer effort
by doctors or patient organisations. It is crucial for the
sustainability of the registry, that these costs are compared
to the possibility of funding.
One future aspect of the ECFSPR is to expand cooper-
ation with the pharmaceutical industry and EMA in order
to collect pharmacovigilance data on new drugs. This
work is in progress in some of the national registries (such
as UK and Germany), but until now the ECFSPR has been
hampered by the three year delay in data collection, which
would not allow timely identification of serious side ef-
fects. However, with the new software, which allows
real-time use in the clinical setting, the possibility of
pharmacovigilance data collection is open for the cen-
tres and countries reporting directly to the ECFSPR.
Finally, missing data is a well-known problem for the
registries without a unique solution. Often missing data
can be avoided by appropriate choice of information to
be recorded, adequate level of detail and coding of infor-
mation, and availability of well-trained, motivated and
dedicated personnel in charge of data retrieval and data
entry. The ECFSPR collects data from national registries
that for some centres have funded data entry, and for
others require data entry in order to be acknowledged as
a CF centre. These are ways to motivate people, but at
the moment, the ECFSPR does not have funding for the
participating centres (and neither any authority over
them). Another way to motivate people is to show them
the utility of the data they have been collecting at regu-
lar feedback sessions as we do with the annual report
and the centre report; and lately with the new software
that offers interactive graphs and tables for use in the
daily clinic management and for patient information.
Conclusions
Setting up and maintaining a disease registry is a bur-
densome venture. Since the tentative beginning in 2003,the ECFSPR has evolved from a small working group of
enthusiastic and knowledgeable national registry repre-
sentatives, collecting data on spreadsheet files with very
little funding and resources, to a professionally run pa-
tient registry with full and part time dedicated personnel
that includes an executive director, an executive coord-
inator, two statisticians, an helpdesk service, a governing
body composed by ten people (Executive Committee), a
bespoke software and extensive use of data collected
from 23 countries and more than 30,000 patients. The
road to this has been paved with obstacles and challenges,
and the journey is by no means at an end. A registry of
these proportions may be initiated, but cannot be run as
an amateur project by a few dedicated people; we could
have probably accomplished our goals faster and have had
fewer bumps on the road had the funding been in place
at an earlier stage. For this reason, we recommend that
objectives, structure and research outcomes are planned
according to the available funding, in order to optimise
resources allocation and avoid early frustration.
In the ECFSPR experience we found crucial for success
the collaboration with existing national and international
registries and cystic-fibrosis organisations (such as the
ECFS Clinical Trial Network). Particularly helpful has
been the patients’ involvement in the registry activities
through their representatives in governance committees
in order to better meet the patients’ needs and to convey
the information about the registry in an effective way
(through the patient-friendly report and the publication of
web pages dedicated to patients in the ECFSPR website).
Another key aspect has been the networking for the
recruitment of new centres to contribute the data, and the
stimulation of their participation through their empower-
ment (participation to the ECFSPR governance bodies),
through fair reward by co-authorship in peer-reviewed
publications, and by publication of periodical (centre-
based) data reports.
Finally, funding is a pivotal aspect in a disease registry
running. The current registry sustainability cost is in
staff (100,000 Euros per year) to retrieve, check, and
analyse the data. But since the real cost to set up the
registry exceeded 1,000,000 Euros over the last decade,
this experience creates a cost-effective approach because
the experience is donated as a gift to the community. A
system for centres accreditation and funding according
to centre’s data completeness and data quality has been
successfully used in many disease registries. This ap-
proach, however, is quite ambitious for most registries,
especially for rare diseases. Pragmatically, where funding
is limited, much can be achieved by restricting the data
collection to a core set of data, usually referring to
demographic, diagnosis and death information, which
are easy to retrieve for most data contributors [9]. The
cost of running a national registry varies depending on
Viviani et al. Orphanet Journal of Rare Diseases 2014, 9:81 Page 14 of 14
http://www.ojrd.com/content/9/1/81the size and organisation of the national registry, and
whether it is used locally for e.g. quality control. The
new ECFSPR software will offer a cheaper solution for
some countries by supplying free software and data
availability locally and nationally.
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